CD8A and breast cancer: Recently, the outcome of ACT in breast cancer has been shown to be enhanced by low-dose Dox (5 mg/kg i.v.) plus Th1 or Th17 cells (i.v. or intratumoral), which results in increased proliferations of CD8+ T-cells and NK cells through elimination of MDSCs [43].